

This facsimile message and its contents are legally privileged and confidential information intended solely for the use of the addressee. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message and its contents is strictly prohibited. If you have received this telecopy in error, please notify us immediately by telephone and return the original message to us at the address shown below via the Postal Service. Thank You.

ALSTON & BIRD LLP

3201 Beechleaf Court, Suite 600
Raleigh, NC 27604-1062
919-862-2200
Fax: 919-862-2260

RECEIVED
CENTRAL FAX CENTER

JUL 07 2004

OFFICIAL

TELECOPY

PLEASE DELIVER AS SOON AS POSSIBLE

Date:

July 7, 2004

Recipient:

MAIL STOP AMENDMENT

Company:

USPTO

Fax Number:

703 872 9306

Voice Number:**Sender:**

Leslie T. Henry

Message:

Re: Appl. No. 09/855,342, filed May 14, 2001

Number of Pages: (including cover page)

13

IF NOT RECEIVED PROPERLY, PLEASE NOTIFY US IMMEDIATELY AT.

USER CODE:	11ENRL	REQUESTED BY:	Lynda, 2233
CLIENT/MATTER:	35784/209112	OPERATOR:	

RECEIVED
CENTRAL FAX CENTER

JUL 07 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

Appl. No.: 09/855,342
Applicant(s): Caligiuri *et al.*
Filed: May 14, 2001
Art Unit: 1642
Examiner: Stephen L. Rawlings
Title:

Confirmation No.: 8842

METHODS OF THERAPY FOR CANCERS CHARACTERIZED BY
OVEREXPRESSION OF THE HER2 RECEPTOR PROTEIN

OFFICIAL

Docket No.: 035784/209112 (5784-50)
Customer No.: 00826

July 7, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT

Sir:

Responsive to the Notice of Non-Compliant Amendment dated June 8, 2004, in the above-identified application, Applicants provide herewith a resubmission of the "Amendments to the Claims" section that was originally submitted in the Amendment filed September 15, 2003, in response to the Office Action dated March 14, 2003. The Examiner is respectfully requested to enter these amendments to the claims into the above-identified application.

Amendments to the Claims are reflected in the listing of claims beginning on page 2 of this paper.

Remarks begin on page 12 of this paper.

R\TA01\2156933v1